Company Monitoring Page for Achillion

latest headlines for company on cafepharma

Biopharma throws grease on the deal wheels
EP Vantage
Wed, 07/21/21 - 10:52 am
Tags:
M&A, Alexion, Achillion, Eli Lilly, Prevail Therapeutics
Alexion Ends Rare Kidney Disease Program Following Poor Data
BioSpace
Fri, 07/31/20 - 11:06 pm
Tags:
Alexion Pharmaceuticals, Achillion, M&A, kidney disease
Alexion dumps ex-Achillion C3G program after seeing phase 2 data
Fierce Biotech
Thu, 07/30/20 - 11:01 am
Tags:
Alexion, Achillion, M&A, clinical trials
After Alexion buyout, ex-Achillion nephrology lead jumps ship to Gemini Therapeutics
Fierce Biotech
Fri, 05/8/20 - 10:21 am
Tags:
Alexion Pharma, Achillion, nephrology, Gemini Therapeutics
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Xconomy
Wed, 10/16/19 - 12:48 pm
Tags:
Alexion Pharmaceuticals, Achillion, M&A, PNH, danicopan, Soliris
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
Endpoints
Wed, 09/25/19 - 11:32 pm
Tags:
Achillion, FDA, paroxysmal nocturnal hemoglobinuria, Soliris, PNH
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
Sat, 05/11/19 - 12:31 pm
Tags:
biotech, Achillion, Sesen Bio, The Medicines Company, Amgen, Daiichi Sankyo, earnings
Achillion Meets Enrollment Target in Kidney Disease Studies
Yahoo/Zacks.com
Thu, 04/4/19 - 12:11 pm
Tags:
Achillion, ACH-4471, kidney disease, clinical trials
Why Achillion Pharmaceuticals, Inc. Stock Spiked Monday
Motley Fool
Mon, 02/26/18 - 07:25 pm
Tags:
Achillion, Europe, kidney disease, ACH-4471
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
Endpoints
Mon, 09/11/17 - 09:40 am
Tags:
JNJ, Achillion, hepatitis C, odalasvir, ACH-3102
J&J advances through PhII with a promising hep C triple and 100% cure rate
Endpoints
Fri, 09/9/16 - 10:21 am
Tags:
JNJ, hepatitis C, clinical trials, odalasvir, AL-335, Olysio, Achillion
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St
Sat, 09/3/16 - 12:17 pm
Tags:
FDA, Achillion, odalasvir, AL-335, simeprevir, Amarin, Vascepa, Array Biopharma, binimetinib, Mast Therapeutics, vepoloxamer, Novavax, Threshold Pharmaceuticals, tarloxotinib
3 Biotechs Expecting Market-Moving Trial Results Soon
Motley Fool
Mon, 06/6/16 - 11:07 am
Tags:
biotech, Ophthotech, Achillion, Kite Pharma, odalasvir, JNJ, Fovista, KTE-C19
Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
Seeking Alpha
Wed, 05/25/16 - 11:31 am
Tags:
Achillion, ACH-4471, JNJ, hepatitis C
Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson
Motley Fool
Thu, 03/31/16 - 11:05 am
Tags:
JNJ, drug development, M&A, Geron, Achillion
3 Small-Cap Biotech Stocks With Big News Coming in 2016
Motley Fool
Sat, 12/12/15 - 02:05 pm
Tags:
biotech, Ophthotech, Fovista, andexanet alfa, Portola Pharmaceuticals, ACH-3102, Achillion
4 Key FDA Decisions Expected By Year End
24/7 Wall St
Sun, 11/29/15 - 12:43 pm
Tags:
FDA, Achillion, hepatitis C, Biocryst, OPuS-2, BCX4161, Tetraphase Pharmaceuticals, Lucitanib, Clovis Oncology
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Motley Fool
Tue, 09/29/15 - 09:04 am
Tags:
Gilead Sciences, hepatitis C, Harvoni, Sovaldi, AbbVie, Viekira Pak, Achillion
Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo
Bidness, ETC
Fri, 09/18/15 - 10:56 am
Tags:
JNJ, Achillion, hepatitis C, Sovaldi, Gilead Sciences, ACH-3102, odalasvir
What Will Gilead Buy Next? 4 Possible Targets
Investors.com
Wed, 07/15/15 - 06:30 pm
Tags:
Gilead Sciences, M&A, Incyte, Vertex Pharmaceuticals, Bristol-Myers Squibb, Achillion

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.